Eline Menu

6.0k total citations · 1 hit paper
131 papers, 4.3k citations indexed

About

Eline Menu is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Eline Menu has authored 131 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Molecular Biology, 83 papers in Hematology and 48 papers in Oncology. Recurrent topics in Eline Menu's work include Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (27 papers) and Histone Deacetylase Inhibitors Research (23 papers). Eline Menu is often cited by papers focused on Multiple Myeloma Research and Treatments (81 papers), Protein Degradation and Inhibitors (27 papers) and Histone Deacetylase Inhibitors Research (23 papers). Eline Menu collaborates with scholars based in Belgium, France and United States. Eline Menu's co-authors include Karin Vanderkerken, Els Van Valckenborgh, Elke De Bruyne, Kim De Veirman, Ken Maes, Jinheng Wang, Hendrik De Raeve, Ivan Van Riet, Ben Van Camp and Miguel Lemaire and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Eline Menu

125 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone marrow stromal cell–derived exosomes as communicators in drug resistance in multiple myeloma cells

2014 366 citations Jinheng Wang, Miguel Lemaire et al. profile →

Peers

Countries citing papers authored by Eline Menu

Since Specialization

Citations

This map shows the geographic impact of Eline Menu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eline Menu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eline Menu more than expected).

Fields of papers citing papers by Eline Menu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eline Menu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eline Menu. The network helps show where Eline Menu may publish in the future.

Co-authorship network of co-authors of Eline Menu

This figure shows the co-authorship network connecting the top 25 collaborators of Eline Menu. A scholar is included among the top collaborators of Eline Menu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eline Menu. Eline Menu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), Fabien Théry, (unknown), (unknown), (unknown), (unknown), (unknown), Kim De Veirman, Karin Vanderkerken, Elke De Bruyne, Lorenzo Franceschini, Francis Impens, Rein Verbeke, Ine Lentacker, Eline Menu, Karine Breckpot	0
2	The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse 2025 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Catharina Olsen, Nathan De Beule, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne	2
3	AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies 2024 ·Experimental Hematology and Oncology ·(unknown), Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman	4
4	Fueling CARs: metabolic strategies to enhance CAR T-cell therapy 2024 ·Experimental Hematology and Oncology ·(unknown), Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu	17
5	Hypoxic Bone Marrow Stromal Cells Secrete miR-140–5p and miR-28–3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma 2023 ·Cancer Research ·(unknown), Zhimin Du, (unknown), (unknown), Eline Menu, Jinheng Wang	8
6	Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis 2023 ·The Journal of Pathology ·(unknown), (unknown), Gamze Ates, Sylvia Faict, Philip Vlummens, (unknown), Rong Fan, Anke Maes, Ann Massie, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Eline Menu	12
7	RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma 2023 ·Frontiers in Immunology ·(unknown), Susanne Beck, Vladimı́r Beneš, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose	3
8	Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman	30
9	Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis 2022 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), Philip Vlummens, (unknown), Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman, Eline Menu	26
10	The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers 2022 ·Frontiers in Immunology ·Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman	15
11	Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma 2021 ·Molecular Omics ·Esther A. Zaal, Harm‐Jan de Grooth, (unknown), (unknown), (unknown), (unknown), Jeroen W. A. Jansen, Eline Menu, Wei Wu, Celia R. Berkers	15
12	A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma 2021 ·Cell Death and Disease ·(unknown), (unknown), Jakob Haglöf, Elke De Bruyne, Eline Menu, (unknown), Anqi Ma, Jian Jin, Fredrik Öberg, Karin Vanderkerken, Antonia Kalushkova, Helena Jernberg‐Wiklund	16
13	The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma 2019 ·Frontiers in Genetics ·Philip Vlummens, Kim De Veirman, Eline Menu, Elke De Bruyne, Fritz Offner, Karin Vanderkerken, Ken Maes	5
14	Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion 2017 ·Cancer Immunology Research ·Kim De Veirman, Nathan De Beule, Ken Maes, Eline Menu, Elke De Bruyne, Hendrik De Raeve, Karel Fostier, Jérôme Moreaux, Alboukadel Kassambara, Dirk Hose, Roy Heusschen, Helena Eriksson, Karin Vanderkerken, Els Van Valckenborgh	44
15	Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression 2017 ·Cancer Research ·Eva De Smedt, Ken Maes, Stefaan Verhulst, Hui Lui, Alboukadel Kassambara, Anke Maes, Nicolas Robert, Carlo Heirman, Andrew Cakana, Dirk Hose, Karine Breckpot, Leo A. van Grunsven, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne	30
16	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement 2016 ·Clinical Cancer Research ·Leo Rasche, Emmanuelle Ménoret, Valentina Dubljevic, Eline Menu, Karin Vanderkerken, Constantin Lapa, Torsten Steinbrunn, Manik Chatterjee, Stefan Knop, (unknown), Deanne L.V. Greenwood, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Stephanie Brändlein	47
17	Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies 2014 ·Frontiers in Oncology ·Kim De Veirman, Els Van Valckenborgh, Qods Lahmar, Xenia Geeraerts, Elke De Bruyne, Eline Menu, Ivan Van Riet, Karin Vanderkerken, Jo A. Van Ginderachter	88
18	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro 2013 ·Molecular Cancer Therapeutics ·Jinsong Hu, Els Van Valckenborgh, Dehui Xu, Eline Menu, Hendrik De Raeve, (unknown), Song Xu, Ben Van Camp, Damian Handisides, Charles P. Hart, Karin Vanderkerken	49
19	The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin 2012 ·Clinical Cancer Research ·Miguel Lemaire, (unknown), Prasoon Agarwal, Eline Menu, Els Van Valckenborgh, Elke De Bruyne, Anders Österborg, Peter Atadja, Olle Larsson, Magnus Axelson, Ben Van Camp, Helena Jernberg‐Wiklund, Karin Vanderkerken	13
20	Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model 2006 ·Clinical & Experimental Metastasis ·Eline Menu, Evy De Leenheer, Hendrik De Raeve, Les Coulton, Takeshi Imanishi, Kazuyuki Miyashita, Els Van Valckenborgh, Ivan Van Riet, Ben Van Camp, Richard Horuk, Peter I. Croucher, Karin Vanderkerken	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact